Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
Research output: Contribution to journal › Article › peer-review
83Scopus
citations
Fingerprint
Dive into the research topics of 'Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies'. Together they form a unique fingerprint.